Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by Cantwinemallon Jun 10, 2018 8:21pm

80 Views

Post# 28152401

RE:RE:June 2018 corporate presentation

Maybe they started working on in April and just completed it with the info. Could have been saved with the april file name. Either way, not a biggie. Its the content that matters.

DatAssBandit wrote:

Cantwinemall wrote: Just added on Kaly website. Check it out. Its awesome.

https://kalytera.co/wp-content/uploads/2018/06/Kalytera-Corporate-Presentation-April-2018.pdf

How come the link says April 2018? Genuinely curious.